BORELLI, BEATRICE
 Distribuzione geografica
Continente #
NA - Nord America 1.029
EU - Europa 511
AS - Asia 163
AF - Africa 47
SA - Sud America 2
Totale 1.752
Nazione #
US - Stati Uniti d'America 1.018
IT - Italia 269
SG - Singapore 78
SE - Svezia 71
CN - Cina 57
GB - Regno Unito 46
BG - Bulgaria 45
DE - Germania 26
CI - Costa d'Avorio 25
NG - Nigeria 14
FR - Francia 13
VN - Vietnam 13
PL - Polonia 12
AT - Austria 11
CA - Canada 11
HK - Hong Kong 6
IN - India 6
FI - Finlandia 5
SN - Senegal 5
CZ - Repubblica Ceca 3
ES - Italia 3
RU - Federazione Russa 3
CH - Svizzera 2
KE - Kenya 2
CL - Cile 1
CO - Colombia 1
EG - Egitto 1
IE - Irlanda 1
IL - Israele 1
KZ - Kazakistan 1
MY - Malesia 1
UA - Ucraina 1
Totale 1.752
Città #
Fairfield 161
Chandler 107
Woodbridge 105
Ashburn 83
Seattle 74
Wilmington 61
Cambridge 54
Milan 46
Sofia 44
Florence 42
New York 42
Houston 39
Boardman 29
London 29
Singapore 27
Ann Arbor 26
Abidjan 25
Pisa 23
Princeton 23
Lawrence 22
Beijing 18
Bremen 18
Medford 16
Lagos 14
Ogden 14
Serra 14
Rome 12
Warsaw 12
Vienna 11
Des Moines 10
Ottawa 10
Seacroft 10
Dearborn 9
Genoa 9
Nanjing 8
Kent 6
Kunming 6
Redwood City 6
Verona 6
Dakar 5
Carrara 4
Dong Ket 4
Hong Kong 4
Nanchang 4
Palermo 4
San Diego 4
Capannori 3
Gargallo 3
Hefei 3
Helsinki 3
Lancaster 3
Los Angeles 3
Munich 3
Osimo 3
Washington 3
Anzio 2
Bari 2
Bern 2
Brno 2
Dallas 2
Ferriere 2
Frankfurt am Main 2
Hebei 2
Lucca 2
Marina di Ravenna 2
Marseille 2
Modena 2
Monte Urano 2
Moscow 2
Norwalk 2
Noventa di Piave 2
Phoenix 2
Piacenza 2
Pistoia 2
San Francisco 2
Santa Maria A Monte 2
Shenyang 2
Turin 2
Vitry-sur-seine 2
Almaty 1
Barcelona 1
Bellinzago Novarese 1
Berlin 1
Berlingo 1
Buffalo 1
Cairo 1
Catania 1
Central 1
Changsha 1
Chiswick 1
Città della Pieve 1
Clifton 1
Cutrofiano 1
Fiumefreddo Di Sicilia 1
Frattamaggiore 1
Fremont 1
Gallarate 1
Guangzhou 1
Hanoi 1
Kells 1
Totale 1.396
Nome #
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 114
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 112
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 108
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 97
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 90
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 89
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 88
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 88
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 81
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 75
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 75
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 72
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 71
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 66
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 66
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 66
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 62
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 59
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 49
Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial) 47
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 42
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 41
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 41
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 39
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 29
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 24
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 12
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 11
Totale 1.814
Categoria #
all - tutte 7.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.249


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020344 0 0 0 33 53 53 50 48 46 32 23 6
2020/2021158 11 9 9 16 1 17 3 14 29 11 18 20
2021/2022184 2 2 2 0 33 32 4 5 10 20 17 57
2022/2023433 33 69 23 39 48 47 22 25 59 3 58 7
2023/2024348 26 37 54 33 47 44 19 11 6 6 40 25
2024/202598 18 47 25 8 0 0 0 0 0 0 0 0
Totale 1.814